Fertility
Genea Biomedx and Future Fertility develop scientific partnership to streamline oocyte quality assessment and improve clinical outcomes in fertility labs
Future Fertility’s oocyte tools will be available for automatic integration within the Geri Time-lapse incubator
Future Fertility’s new integration with Genea Biomedx’s Geri time-lapse incubators enables labs to seamlessly generate personalised oocyte quality reports for patients, adding to Geri’s proven ability to improve clinical outcomes and efficiency.
On the heels of a recent acquisition by Basecare, Genea Biomedx, manufacturer of medical devices for IVF laboratories including Geri, the world-first and world’s only humidified time-lapse incubator, announced a strategic scientific partnership with Future Fertility, the global leader in oocyte assessment tools.
Future Fertility’s oocyte tools will be available for automatic integration within the Geri Time-lapse incubator as an optional value-added feature for Geri clients globally.
With over two thirds of fertility cycles failing on average globally, it is critical for clinicians and embryologists to understand all variables and to use top-quality medical devices for all stages of the process.
While it is well understood that the oocyte plays a critical role in embryo development, there is no current standard of care for oocyte assessment, which leaves embryologists and physicians to rely upon age and number of mature eggs to estimate egg quality.
Validated in over eight regions, live in over 15 countries and used in over 70 clinics globally, Future Fertility’s AI tools empower patients and clinicians to make more informed decisions along the IVF journey.
Validation studies have demonstrated an approximate 20 per cent improvement over embryologist assessments, and a 100 per cent repeatability rate in predictions.
Studies have also proven a strong correlation between Magenta scores and embryo quality, with scores outperforming prediction models built based on age alone, demonstrating the importance of personalised oocyte assessments and their role in clinical practice.

Geri has an established presence in over 600 laboratories globally and its use resulted in statistically significant improvements in embryo development and clinical outcomes, including a 24 per cent increased clinical pregnancy rate, in comparison to a conventional culture system.
As the world’s only humidified time-lapse incubator and with individualized patient culture, Geri presents a premium offering to laboratories aiming to achieve the best quality embryos and the fastest time to pregnancy.
Integration between Future Fertility and Geri enables clinics to pull oocyte AI reports in real-time, saving the clinic time as images are automatically collected in the background from Geri. This streamlines lab processes, simplifying access to oocyte assessments which are available in as little as three seconds.
Geri customers will benefit from hands-off software set-up and improved lab efficiency, in addition to an enhanced patient experience from the patient-friendly counselling reports, complementing Geri’s ability to bring greater efficiency via remote monitoring and automated annotation of embryos.
“The importance of choosing the right tools to culture and select embryos has never been more obvious, and AI-powered decision support tools are emerging as a new standard of care in fertility treatments,” said Tom Beckitt, COO of Genea Biomedx.
“In our company’s commitment to developing fertility technologies that improve clinical outcomes, the integration of Future Fertility’s clinically validated oocyte assessment software alongside Geri Connect & Geri Assess provides our customers not only with lab efficiencies, but also new AI-powered insights that were not previously observable by embryologists alone.”
Future Fertility’s CEO, Christy Prada, expressed her excitement about this innovative partnership, stating: “We’re thrilled to collaborate to streamline embryologists’ workflows and deliver more value to their ICSI IVF patients through easy access to our personalised oocyte quality reports.
“Genea Biomedx’s commitment to quality is evidenced through their uniquely designed Geri time-lapse incubator, and we are grateful to partner with a leader in the field.”

Entrepreneur
Kindbody unveils next-gen fertility platform
Fertility
Baby2Home app boosts new mothers’ mental health
First-time mothers using the Baby2Home app for a year after birth reported fewer symptoms of stress, depression and anxiety than those receiving usual postpartum care.
The study found women randomised to the app reported better overall health than first-time mothers who received usual care alone.
Baby2Home is a digital tool to help new families with newborn care and staying healthy.
It offers tailored educational content, infant care trackers and mental health self-management tools, plus access to a care manager for on-demand mental health and problem-solving support.
Emily S. Miller is principal investigator and division director of maternal-fetal medicine at Women & Infants Hospital of Rhode Island.
She said: “Evidence-based digital tools like Baby2Home are opening the door to a new era of postpartum care.
“We can now extend high-quality support beyond hospital walls and into families’ everyday lives. The mental health improvements we saw underscore just how transformational that support can be.”
Researchers from Women & Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Northwestern University’s Feinberg School of Medicine and Lurie Children’s Hospital of Chicago ran a multi-site randomised controlled trial between November 2022 and July 2025.
The trial enrolled 642 postpartum patients, all first-time parents. For 12 months after birth, all participants received usual postpartum care; half also used the Baby2Home smartphone app.
Participants reported progress electronically at five time points over the first year. Compared with the control group, those assigned to Baby2Home reported significantly fewer symptoms of stress, depression and anxiety.
They also reported better overall health, higher relationship satisfaction with partners and family members, and greater confidence in their parenting than the control group.
Miller said: “The first year after birth is a critical period for parental mental health. Baby2Home helped new parents feel more confident, more supported and more connected.
“That translated into better health outcomes for them and their families.”
Fertility
Most NHS regions in England limit IVF to single cycle, research finds
Nearly 70 per cent of NHS regions in England fund only one IVF cycle for women under 40, breaking national guidelines, new research has found.
Twenty-nine of the 42 integrated care boards, which control local NHS budgets, now offer only one round of treatment, after four reduced access in the past year.
National Institute for Health and Care Excellence (Nice) guidelines recommend three full cycles for women under 40 who have been unable to conceive for two years.
Only two of England’s 42 integrated care boards have policies consistent with these guidelines, which they are not legally obliged to follow.
The research was conducted by the Progress Educational Trust, a fertility charity.
Sarah Norcross, the director of PET, said the impact was “devastating” for couples struggling with infertility.
She said: “Infertility is already incredibly stressful for people, and it puts them under even more pressure, because there is so much riding on whether that one NHS-funded cycle is going to work.
“And for some people, that will be their only chance, because private fertility treatment is so expensive.”
The data showed regional variations, with the whole of the north-west offering just one cycle.
“It’s a postcode lottery, and we’re seeing a race to the bottom,” said Norcross.
Of the 29 integrated care boards that offer a single cycle, 19 provide only a partial cycle, where not all viable embryos created are transferred.
There was just one recent example of improved services, from NHS South East London, which in July 2024 went from one partial to two full cycles.
The NHS estimates that about one in seven couples may have difficulty achieving a pregnancy. One cycle of IVF can cost from £5,000 at a private clinic.
Fertility rates in England and Wales have fallen since 2010 to 1.41 children per woman in 2024, the lowest on record and below the replacement level of 2.1 at which a population is stable without immigration.
Health minister Karin Smyth said in a written parliamentary answer last month that it was “unacceptable” that access to NHS-funded fertility services varied across the country.
Revised Nice fertility guidelines are due this spring, but Norcross said changing them seemed pointless.
She said: “Fertility treatment has always been a Cinderella service. It’s always been the one they’ve chosen to cut or to ignore.
“Nice has recommended three full NHS-funded cycles, for women under 40, for more than 20 years. This has never been implemented across England, unlike in Scotland.”
Norcross advocated centralised commissioning and replicating Scotland’s approach, which included financial modelling and a phased implementation starting with two cycles to avoid long waits, moving up to three once capacity was achieved.
“It is a tried and tested plan that England could follow,” Norcross added.
A Department of Health and Social Care spokesperson said: “We recognise access to fertility treatment varies across the country and we are working with the NHS to improve consistency.
“Nice provides clear clinical guidelines, and we expect integrated care boards to commission treatment in line with these.
“Updated Nice fertility guidelines are expected this spring and we will continue to support NHS England to make sure the guidance is fully considered in local commissioning decisions.”
An NHS England spokesperson said: “These clinical services are commissioned by integrated care boards for their area based on the needs of the local population and prioritisation of resources available.
“All ICBs have a responsibility to ensure services are provided fairly and are accessible by different population groups.”
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Hormonal health2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment